亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

供應(yīng) 格列美脲原料藥

 
 
單價 1.00 / KG對比
銷量 暫無
發(fā)貨 湖北武漢市付款后24小時內(nèi)
庫存 10000KG起訂1KG
品牌 格列美脲原料藥
cas 登入號 93479-97-1
過期 長期有效
更新 2014-11-12 09:43
 

武漢東康源科技有限公司

企業(yè)會員第12年
資料未認證
保證金未繳納
詳細說明
     格列美脲原料藥廠家對格列美脲原料藥行情、價格、參數(shù)進行的詳細介紹。
 
一.下面由東康源為您對格列美脲原料藥做一番簡單的介紹:
1.cas 登入號:93479-97-1
2.產(chǎn)品分子式:C24H34N4O5S
3.產(chǎn)品分子量:490.6156
4.外觀和性狀:白色結(jié)晶粉末
5.作用及用途:用作降血糖藥
 
二.如果還想詳細了解格列美脲原料藥的話,不妨看看下面的參數(shù):
1.中文名稱:格列美脲
2.中文別名:格列美吡拉;格列吡咯;賀普丁
3.化學名稱:1-[4-[2-(3-乙基-4-甲基-2-氧代-3-吡咯啉-1-甲酰胺基)-乙基]-苯磺酰]-3-(反式-4-甲基環(huán)己基)-脲;反式-3-乙基-2,5-二氫-4-甲基-N-[2-[4-[[[[(4-甲基環(huán)己基)氨基]羰基]氨基]磺酰基]苯基]乙基]-2-氧-1H-吡咯-1-羧酰胺
4.英文名稱:Glimepiride
 
    假如您還心存疑惑的話,歡迎致電格列美脲原料藥生產(chǎn)廠家東康源咨詢格列美脲原料藥價格、格列美脲原料藥廠家、格列美脲原料藥供應(yīng)商以及其他方面的信息。
舉報收藏 0評論 0
更多>本企業(yè)其它產(chǎn)品
硝酸益康唑 醋酸洗必泰 磺胺間二甲氧嘧啶 普盧利沙星 周效磺胺 吲哚美辛 妥曲珠利 替硝唑
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |